Literature DB >> 16369392

NSAID hysteria--Chicken Little revisited.

John A Goldman1, Sanford S Hartman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16369392      PMCID: PMC1681584     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


× No keyword cloud information.
  14 in total

1.  Discontinuation of Vioxx.

Authors:  Michel Lièvre; Eric Abadie
Journal:  Lancet       Date:  2005 Jan 1-7       Impact factor: 79.321

2.  Raising the safety bar--the FDA's coxib meeting.

Authors:  Susan Okie
Journal:  N Engl J Med       Date:  2005-03-31       Impact factor: 91.245

3.  Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Authors:  Scott D Solomon; John J V McMurray; Marc A Pfeffer; Janet Wittes; Robert Fowler; Peter Finn; William F Anderson; Ann Zauber; Ernest Hawk; Monica Bertagnolli
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

4.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

Authors:  Nancy A Nussmeier; Andrew A Whelton; Mark T Brown; Richard M Langford; Andreas Hoeft; Joel L Parlow; Steven W Boyce; Kenneth M Verburg
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

5.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

6.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

7.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

8.  Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.

Authors:  Stephen E Kimmel; Jesse A Berlin; Muredach Reilly; Jane Jaskowiak; Lori Kishel; Jesse Chittams; Brian L Strom
Journal:  Ann Intern Med       Date:  2005-02-01       Impact factor: 25.391

9.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

Authors:  Peter Jüni; Linda Nartey; Stephan Reichenbach; Rebekka Sterchi; Paul A Dieppe; Matthias Egger
Journal:  Lancet       Date:  2004 Dec 4-10       Impact factor: 79.321

10.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.